Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
- Status
- TERMINATED
- Phase
- PHASE1
Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Agaricus Blazei Murill in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
- Status
- WITHDRAWN
- Phase
- PHASE2
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
SCRI Tissue Testing Registry
- Status
- TERMINATED
- Phase
- N/A
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
- Status
- TERMINATED
- Phase
- PHASE1
RMPT for Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Skin Biopsies in Chemotherapy-Induced Neuropathy
- Status
- COMPLETED
- Phase
- N/A
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
- Status
- COMPLETED
- Phase
- PHASE1
Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2